Immucell Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by te Boekhorst Paul Francis Olivier, was filed 04 Dec 2025.
Immucell Corp: what insiders have been doing
Immucell Corp is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). In the past year (24 October 2025 to 24 October 2026), 9 filings came from 3 insiders.
No insider sold shares on the market over the period. Instead, the filings list 7 purchases totalling €82k, made by 2 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 senior executive and 1 chief executive. The largest single trade was a purchase of €16k by te Boekhorst Paul Francis Olivier, published on 4 December 2025.
In the case of 5 purchases, another manager of the company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 4 December 2025, 339 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade.
For context, the typical company on the same exchange (median of 3,167 companies) published 24 filings over the same period, against 9 filings here. The full history, which starts in 2006, counts 305 purchases against 30 sales. The 10-K for the year ended 31 December 2025 shows 27.6 m USD of revenue and -1.0 m USD of net income.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- +85.1%Entry US$5.64 · Close 22 Oct 2026 US$10.44
- +120.3%Entry US$4.74 · Close 22 Oct 2026 US$10.44
- +46.8%Entry US$6.49 · Close at T+365 US$9.53
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 25,000 shares@ US$5.840.15% mcap50.0% of flowCommon Stock, par value $.01 per shareSEC:0001437749-26-009661:0
- 24,052 shares@ US$6.070.15% mcap50.0% of flowCommon Stock, par value $.01 per shareSEC:0001437749-26-009661:1
- 2,432 shares@ US$5.5016.6% of flowCommon Stock $0.10 par value per shareSEC:0001437749-25-036913:1Canonical exit: 4 Mar 2026 (T+90)
- 3,598 shares@ US$5.04550.1% of flowCommon Stock $0.10 par value per shareSEC:0001437749-25-036913:0Canonical exit: 3 Mar 2026 (T+90)
- 2,556 shares@ US$5.0016.0% of flowCommon Stock $0.10 par value per shareSEC:0001437749-25-036794:1Canonical exit: 3 Mar 2026 (T+90)
- 3,521 shares@ US$5.0422.2% of flowCommon Stock $0.10 par value per shareSEC:0001437749-25-036794:2Canonical exit: 3 Mar 2026 (T+90)
- 3,708 shares@ US$4.868649.9% of flowCommon Stock $0.10 par value per shareSEC:0001437749-25-036794:0Canonical exit: 2 Mar 2026 (T+90)
- 1,633 shares@ US$4.772.0% of flowCommon Stock $0.10 par value per shareSEC:0001437749-25-036477:1Canonical exit: 23 Feb 2026 (T+90)
- 1,633 shares@ US$4.767.4% of flowCommon Stock $0.10 par value per shareSEC:0001437749-25-036477:0Canonical exit: 23 Feb 2026 (T+90)
- 3,530 shares@ US$4.81100.0% of flowCommon stock $0.10 per value per shareSEC:0001213900-25-054188:0
- 1,000 shares@ US$6.32100.0% of flowCommon stock $0.10 per value per shareSEC:0001213900-25-053904:0Canonical exit: 10 Sept 2025 (T+90)
- 2,186 shares@ US$3.557.6% of flowCommon stock $0.10 per value per shareSEC:0001213900-24-074326:0
- 6,005 shares@ US$3.5520.9% of flowCommon stock $0.10 per value per shareSEC:0001213900-24-072552:0
- 10,000 shares@ US$3.5534.8% of flowCommon stock $0.10 per value per shareSEC:0001213900-24-071759:0
- 4,811 shares@ US$3.724.7% of flowCommon stock $0.10 per value per shareSEC:0001213900-24-070559:1
- 3,172 shares@ US$3.673.0% of flowCommon stock $0.10 per value per shareSEC:0001213900-24-070559:2
- 2,017 shares@ US$3.5677.1% of flowCommon stock $0.10 per value per shareSEC:0001213900-24-070559:0
- 3,100 shares@ US$4.754115.0% of flowCommon stock $0.10 per value per shareSEC:0001213900-23-074246:0
- 300 shares@ US$5.240.4% of flowCommon Stock, $0.10 per value per shareSEC:0001213900-23-020267:1
- 200 shares@ US$5.250.3% of flowCommon Stock, $0.10 per value per shareSEC:0001213900-23-020267:2
- 900 shares@ US$5.371.3% of flowCommon Stock, $0.10 per value per shareSEC:0001213900-23-020267:3
- 80 shares@ US$5.340.1% of flowCommon Stock, $0.10 per value per shareSEC:0001213900-23-020267:4
- 3 shares@ US$5.240.0% of flowCommon Stock, $0.10 per value per shareSEC:0001213900-23-020267:5
- 7 shares@ US$5.240.0% of flowCommon Stock, $0.10 per value per shareSEC:0001213900-23-020267:6
- 10 shares@ US$5.230.0% of flowCommon Stock, $0.10 per value per shareSEC:0001213900-23-020267:7
25 of 417 declarations
About Immucell Corp
ImmuCell Corp /DE/ (ticker: ICCC) is a Nasdaq-listed company in the United States focused on animal health and, more specifically, biologics for calves. Founded in 1982 and taken public in 1987, the company shifted its strategic emphasis in the late 1990s toward dairy and beef applications after obtaining USDA approval to market First Defense® in 1991. Its headquarters are in Portland, Maine. ImmuCell remains a niche operator rather than a broad-based animal-health platform, with a portfolio centered on a few core products and a strong technical specialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/811641/000121390016011870/f10k2015_immucellcorp.htm?utm_source=openai))
The company’s main business is the development, manufacturing, and commercialization of the First Defense® line, designed to provide immediate immune protection to newborn dairy and beef calves against scours (neonatal calf diarrhea). Management positions this condition as a major economic burden for the U.S. cattle industry and frames First Defense as a biologic, USDA-licensed scours-prevention franchise. ImmuCell also continues to develop Re-Tain®, a treatment candidate for subclinical mastitis in lactating dairy cows, although this program has experienced regulatory and accounting-related setbacks, including recent asset write-downs. ([immucell.com](https://immucell.com/investors/))
Read moreShow less
From a competitive standpoint, ImmuCell’s differentiation comes from proprietary biologic know-how and its scale in hyperimmunized bovine colostrum processing. The company states that it is the only animal-health company able to hyperimmunize bovine colostrum commercially, which supports its positioning in a specialized, high-barrier niche. Rather than competing as a diversified animal-health conglomerate, ImmuCell competes on product efficacy, manufacturing capability, and on-farm economic value. Its market exposure is primarily tied to North American dairy and beef production, where adoption is driven by calf survival, productivity, and reduced dependence on antibiotics. ([immucell.com](https://immucell.com/about-immucell/our-purpose/?utm_source=openai))
Recent developments suggest a meaningful operational improvement. In its March 2026 release covering full-year 2025 results, ImmuCell reported product sales of approximately $27.6 million, up 4.3% year over year, gross margin of 41.4% versus 30.0% in 2024, and net operating income of $1.6 million. Management attributed the improvement to higher volumes, better manufacturing efficiency, and improved price realization, while also noting one-time items linked to Re-Tain® and CEO transition costs. The company also highlighted an increase in average monthly output and a continued focus on yield improvement. For investors, ICCC is a small-cap Nasdaq animal-health story in the United States with a focused product set, a defensible niche, and a profile that depends heavily on execution in manufacturing, commercialization, and regulatory development. ([immucell.com](https://immucell.com/wp-content/investor-assets/press-releases/2026/Rel2026-03-04-lttrhead.pdf))
